Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Neuralstem rebounds on additional MDD data

December 6, 2017 12:09 AM UTC

Neuralstem Inc. (NASDAQ:CUR) gained $1.97 (176%) to $3.09 on Tuesday after reporting additional data from a Phase II trial of NSI-189 to treat major depressive disorder.

In July, the company's stock fell 50% to $2.81 after reporting top-line data showing that both doses of NSI-189 missed the trial's primary endpoint of improving Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline to week 12 vs. placebo (see BioCentury Extra, July 25)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Seneca Biopharma Inc.